FDA v. Alliance for Hippocratic Medicine

The Supreme Court unanimously ruled that a group of doctors and medical associations did not have the legal right to challenge the FDA's decisions about the abortion pill mifepristone. The Court found that the plaintiffs lacked standing (the legal right to sue) because they could not show they were directly harmed by the FDA's 2016 and 2021 regulatory changes. Because the plaintiffs did not have the right to be in court, the justices did not rule on whether the FDA's actions were actually legal or safe.

This decision ensures that mifepristone remains available under the current rules, which allow the drug to be sent through the mail and prescribed by health providers who are not doctors. Millions of people who use medication for abortion or miscarriage care will not see immediate changes to how they access these prescriptions. The ruling also protects the FDA's authority to make scientific decisions about drug safety without being easily sued by groups who disagree with those choices.

The case was a major test of how much power outside groups have to challenge federal agencies in court. By requiring a clear, personal injury to sue, the Court limited the ability of organizations to use the legal system to overturn government policies they dislike. This decision follows years of intense political and legal battles over reproductive rights across the United States.

The Court reached a unanimous 9-0 decision to reverse the lower court's ruling, with the opinion emphasizing that the plaintiffs failed to meet the requirements for standing.

“The Court has long rejected this 'if not us, who' argument regarding the plaintiffs' ability to challenge the FDA's actions.”

Mifepristone remains legal and available as the Court dismissed the challenge because the plaintiffs had no legal standing to sue.

Observers will now watch how lower courts and state governments respond to this ruling in other pending cases. While this specific lawsuit is over, other groups or states may try to find new legal ways to challenge the FDA's rules. Federal agencies will continue to implement the 2016 and 2021 guidelines for medication access.

The case focused on whether the FDA followed proper procedures when it made mifepristone easier to access in 2016 and 2021. Plaintiffs argued these changes were unsafe, while the FDA defended its scientific review process.

Patients can continue to receive mifepristone through the mail and at pharmacies as previously allowed. The ruling prevents a nationwide ban or restriction on the drug that the lower courts had suggested.

The Court applied the rule of Article III standing, which requires plaintiffs to prove they suffered a concrete injury. The justices found the doctors' concerns were too speculative to allow the lawsuit to proceed.

The case returns to the lower courts to be formally closed following the Supreme Court's instructions. Legal experts will monitor if different plaintiffs with different claims attempt to bring similar challenges.

This ruling shows the Court's current hesitation to allow broad challenges to federal agency decisions. It reinforces strict requirements for who can sue the government over nationwide policies.